Table. Summary of clinical features for 14 patients with Mycobacterium lentiflavum infection*.
Patient no. (ref. no.) | Age | Sex | Concomitant disease | Intercurrent treatment | Side of infection | Susceptibility test | Antimycobacterial therapy | Clinical outcome |
---|---|---|---|---|---|---|---|---|
1 (3) | 19 mo | M | No | No | Cervical lymph node | No | Surgical excision | Recovery (resolved) |
2 (4) | 42 mo | M | No | No | Cervical lymph node | No | Surgical excision | Recovery |
3 (4) | 33 mo | M | No | No | Cervical lymph node | No | Surgical excision | Recovery |
4 (2) | 6 y | F | No | No | Cervical lymph node | ND | Rif, clm/3 wk surgical excision | Recovery |
5 (2) | 4 y | F | ND | ND | Cervical lymph node | ND | Inh, rif/† surgical excision | Recovery |
6 (2) | 4 y | M | ND | ND | Cervical lymph node | ND | surgical excision | Recovery |
7 (6) | 3 y | M | No | No | Cervical lymph node | ND | Clm, eth/6mo | Persistent suppuration |
8 (I7) | 52 y | F | Antisynthetase syndrome | Corticosteroid | Synovial fluid of wrist | inh R, rif R, str R, eth R, pza R, cys S | inh, rif, eth, pza/† fus, levo, clm/1wk | Exitus |
9 (8) | 49 y | M | HIV infection | HAART | Blood, lung | clm S, rib S | clm, rib, eth/4mo | Recovery |
10 (1) | 85 y | F | Diabetes mellitus | ND | Thoracic vertebrae | No | inh, rif, pza/3mo Inh, rif/6mo | Improvement |
11 (2) | 58 y | M | Rheumatoid arthritis | Corticosteroid | Lung | ND | inh, rib, eth, pza/4mo | No improvement |
12 (2) | 61 y | F | COPD, ovarian carcinoma | Reiterated chemotherapy | Lung | ND | rif, inh, pza/† rib, eth, clm, cip/† | No improvement (unchanged) |
13 (2) | 45 y | M | HIV infection, NHL | HAART | Hepatic nodular lesion | ND | rib, clm, eth, cip/2 mo Rib, clm/4mo | Recovery |
14 (Molteni) | 70 y | F | COPD, lung fibrodystrophy | No | Lung | inh R, str R, rif R, amik R, km R, pza R, oflox R, clm S, eth S, cys S, ter S, rib S | cip, inh/1mo inh, pza, eth, rif/3mo clm/3mo clm, eth, rib, cip/2wk | No improvement |
*M, male; F, female; ND, not done; COPD, chronic obstructive pulmonary disease; HAART, higly active antiretroviral therapy; amik, amikacin; clm, clarithromycin; cys, cycloserine; eth, ethambutol, fus, fusidic acid; inh, isoniazid; km, kanamycin; levo, levofloxacin; oflox, ofloxacin, pza, pyrazinamide; rib, rifabutin; rif, rifampin, str, streptomycin; ter, terizidon. †Treatment duration not determined.